Glucotrace

Glucotrace is a radiopharmaceutical containing the active ingredient Fluorodeoxyglucose F‑18, supplied as a sterile solution for injection. It is a glucose analog used in diagnostic imaging, primarily for positron emission tomography (PET). The product is authorized in the European Union and is available by prescription only. Its mechanism relies on cellular uptake and phosphorylation, enabling visualization of metabolic activity in various tissues.

Glucotrace is employed in PET imaging to assess metabolic activity in several clinical contexts. It supports diagnostic decision‑making by highlighting areas of increased glycolysis.

- Oncologic PET imaging for tumor detection, staging, and monitoring therapeutic response. - Cardiac PET imaging to evaluate myocardial viability and perfusion. - Neurologic PET imaging for epilepsy focus localization, dementia assessment, and brain tumor evaluation. - Research applications investigating metabolic pathways in experimental settings.

Adverse reactions to Glucotrace are generally infrequent, but they can be categorized by frequency and severity.

Common: - Mild injection site discomfort or erythema. - Transient nausea or vomiting. - Temporary headache. - Low‑grade fever. - Brief dizziness or light‑headedness.

Serious: - Allergic reactions ranging from urticaria to anaphylaxis. - Severe hypotension or cardiovascular collapse. - Acute renal impairment in patients with pre‑existing kidney disease. - Radiation‑related tissue injury in high‑dose exposure scenarios.

Glucotrace should be administered with consideration of patient‑specific factors and institutional safety protocols.

- Verify pregnancy status; the radiopharmaceutical is contraindicated in known or suspected pregnancy due to fetal radiation exposure. - Assess renal function before injection, as impaired clearance may increase radiation dose. - Ensure proper hydration to facilitate renal excretion of the tracer. - Follow radiation safety guidelines for staff, including shielding and exposure monitoring. - Review patient history for prior allergic reactions to radiopharmaceuticals. - Maintain accurate documentation of administered activity and timing for image interpretation.

Glucotrace may interact with other substances that affect glucose metabolism or radiation exposure.

Avoid: - Concurrent administration of high‑dose glucose or insulin that could alter tracer uptake patterns. - Use of other radiopharmaceuticals within 24 hours, which may increase cumulative radiation dose.

Use with caution: - Medications that modify glycolysis, such as metformin, may affect image quality. - Contrast agents used in CT may influence PET/CT interpretation. - Chemotherapeutic agents that cause rapid tumor cell turnover could alter tracer distribution. - Beta‑blockers or other cardiovascular drugs that impact myocardial perfusion. - Any drug that significantly changes blood glucose levels around the time of imaging.